Number of Patients Exhibiting Natural Killer Cell Expansion Day 14 [clinicaltrials_resource:f5f76a2ec11f2ed40389ed4b40905498]
Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of >100 cells/μl 14 days after infusion with <5% donor T and B cells in the mononuclear population.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Number of Patients Exhibiting Natural Killer Cell Expansion Day 14 [clinicaltrials_resource:f5f76a2ec11f2ed40389ed4b40905498]
Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of >100 cells/μl 14 days after infusion with <5% donor T and B cells in the mononuclear population.
Bio2RDF identifier
f5f76a2ec11f2ed40389ed4b40905498
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f5f76a2ec11f2ed40389ed4b40905498
measure [clinicaltrials_vocabulary:measure]
Number of Patients Exhibiting Natural Killer Cell Expansion
time frame [clinicaltrials_vocabulary:time-frame]
description
Successful natural killer (NK) ...... in the mononuclear population.
identifier
clinicaltrials_resource:f5f76a2ec11f2ed40389ed4b40905498
title
Number of Patients Exhibiting Natural Killer Cell Expansion Day 14
@en
type
label
Number of Patients Exhibiting ...... 76a2ec11f2ed40389ed4b40905498]
@en